Steven P. LaRosa

Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis

Steven M. Opal, Pierre‐François Laterre, Bruno François et al. · JAMA · 2013 · 770 citations · Full text

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation*

Jean‐Louis Vincent, M Ramesh, David Ernest et al. · Critical Care Medicine · 2013 · 315 citations

Long-Term Quality of Life Among Survivors of Severe Sepsis: Analyses of Two International Trials*

Sachin Yende, Shamly Austin, Andrew Rhodes et al. · Critical Care Medicine · 2016 · 267 citations · Full text

Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*

Mark Tidswell, William Tillis, Steven P. LaRosa et al. · Critical Care Medicine · 2009 · 220 citations

Systemic Host Responses in Severe Sepsis Analyzed by Causative Microorganism and Treatment Effects of Drotrecogin Alfa (Activated)

Steven M. Opal, Gary Garber, Steven P. LaRosa et al. · Clinical Infectious Diseases · 2003 · 190 citations · Full text